Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals Limited has announced the quotation of 37,949 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 8, 2025. This move is part of an employee incentive scheme, reflecting the company’s commitment to rewarding its workforce and potentially enhancing its market position by aligning employee interests with shareholder value.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$16.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company is primarily involved in creating innovative solutions for cancer treatment and imaging, aiming to enhance patient care through precision medicine.
Average Trading Volume: 2,267,426
Technical Sentiment Signal: Sell
Current Market Cap: A$4.84B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.